De novo minimal change disease after kidney transplantation in a 25 year old patient with history of biopsy proven membranous glomerulopathy (MGN) is described. Post-transplant glomerular diseases (PTGN) have been documented frequently, although majority of them, are recurrences of primary diseases. In some cases, de novo glomerular diseases can develop in recipients. In this paper, a case of de novo minimal change disease (MCD) after non-related live donor kidney transplantation in a patient with a history of biopsy proven membranous nephropathy is described. A 25-year-old man with history of biopsy-proven idiopathic membranous glomerulopathy (MGN) who had been transplanted 3 weeks before referred to hospital, presented with peripheral edema and massive proteinuria. First kidney biopsy was compatible with acute cellular rejection with glomerulitis. The patient was treated with methylprednisolone. Panel reactive antibody (PRA) and C4d were negative. Anti-phospholipase A2 receptor (PLA2R) antibody was also negative. Another allograft biopsy was conducted and the result was highly suggestive of MCD. Thus final diagnosis was de novo MCD and proteinuria decreased successfully.
Introduction
Glomerular disease after renal transplantation is frequently associated with recurrence of primary disease. Proteinuria remarkably diminishes long-term allograft outcome and renal function (1, 2) . Post-transplant glomerular diseases (PTGN) will develop in around 6%-20% of renal allograft recipients and is either recurrence of primary disease or a de novo event (3) . In one study of Canadian population, biopsy proven PTGN was observed in 24.3% of renal allografts (4) . It has been reported in up to 40% of recipients. In some cases, de novo glomerular disease can occur in renal allografts. To our knowledge, de novo MCD is an infrequent complication (5-10) and only about 18 cases have been published while some of them do not completely meet the criteria for the diagnosis (8, 9) . Clinically, patients with de novo MCD present with signs and symptoms of nephrotic syndrome shortly after renal transplantation (5) (6) (7) (8) (9) (10) . Pathologically it is characterized by fusion of epithelial foot processes on electron microscopy (11) . We report a patient who presented with peripheral edema and massive proteinuria 3 weeks after kidney transplantation.
Case Presentation
A 25-year-old man with history of end-stage renal disease (ESRD) due to biopsy-proven idiopathic membranous glomerulopathy (MGN) with the first presentation of 34 g/d proteinuria and pulmonary embolism at age of 18 years, received a non-related live donor kidney transplantation in Afghanistan in November 2016. His immunosuppressive medications in the first visit included tacrolimus 1 mg twice a day, azathioprine 50 mg once a day and prednisolone 25 mg daily. Three weeks after transplantation, he presented with edema of lower extremities, abdominal distention and hypertension. The initial investigation revealed a proteinuria of 11 g/d and a serum creatinine of 1.1 mg/dL. The patient was hospitalized. On admission, azathioprine was discontinued. Immunosuppressive regimen changed to tacrolimus 4 mg twice a day and mycophenolate mofetil 1 g twice a day. The patient also was treated with anti-proteinuric agents in multimodal fashion; valsartan 80 mg daily, spironolactone 25 mg daily, atorvastatin 20 mg daily and calcitriol 0.25 mg daily. A renal allograft biopsy was conducted. Morphologic lesions consisted a severe lymphocytic tubulitis with moderate interstitial inflammation highly suggestive of acute cellular rejection. There was a severe peritubular capillaries (PTCitis) suspicious for antibody mediated rejection too. There was no significant glomerulopathy in the immunofluorescence and light microscopy studies ( Figure 1 ). C4d result was pending. Panel reactive antibody (PRA) by flow cytometry was requested. For initial treatment patient received intravenous methylprednisolone pulse therapy (500 mg) for 3 consecutive days (day 2 to day 4). PRA result was negative and IHC (immunohistochemistry) study for C4d in the PTCs and glomeruli was negative. Additionally no immune reaction was detected on IHC ( Figure 2 ). Anti-phospholipase-A2-receptor (PLA2R) antibody was measured due to high possibility on recurrence of MGN that was negative. On sixth day of admission, the protein excretion decreased to 3.3 g/d, serum creatinine was stable. Peripheral edema gradually decreased. According to morphologic lesions and clinical manifestations and laboratory correlation, a second allograft biopsy was obtained on the eighth day after first biopsy. Microscopic examination revealed cortical kidney tissue with 12 glomeruli and 3 medium-sized arteries. All of the glomeruli, tubules, interstitium and vessels were unremarkable. Glomerulitis, GBM thickening, peritubular capillaritis, tubulitis, interstitial inflammation or endothelialitis was not detected (Figure 3 ). An ultrastructural examination revealed extensive effacement in 75%-80% of visceral foot processes. No GBM thickening, immune-complex type deposit, glomerulitis or sub-endothelial electron lucency was identified ( Figure  4 ). These pathologic findings were highly suggestive of minimal change disease (MCD). The final diagnosis was do novo MCD. The patient was treated with prednisolone 25 mg daily, mycophenolate mofetil 2 g daily and tacrolimus 7 mg daily (trough level was 12 ng/mL). Patient's response was favorable. After 2 weeks of treatment, proteinuria was decreased to 100 mg/day and peripheral edema was significantly reduced. Discussion PTGN can be subdivided both clinically and pathologically into three groups; true recurrence of original disease, transplant glomerulopathy with no previous histological confirmed primary disease and de novo disease which can be defined as new pathology distinguishable from the background disease (5). Occasionally, MCD could develop de novo in renal allografts, however, in literature review only a few reports have been published (6) (7) (8) (9) (10) . Live donor transplant allograft is considered as a risk factor for de novo MCD as seen in our patient (8) . Like our case, most of the published cases were presented in early phases after renal transplantation (6-10,12). Zafarmand et al described 5 new cases of de novo MCD and 9 previously reported cases. Except one of them, de novo MCD occurred in no more than 4 months after transplantation (8) . Acute rejection can also present as nephrotic range proteinuria shortly after transplantation (12) (13) (14) (15) (16) . The first allograft biopsy was highly suggestive of acute cellular rejection. Our patient had also nephrotic range proteinuria, however our first diagnosis was based on this implications. Around 7% to 48% of MGN can recur after renal transplantation (17) (18) (19) . Anti-phospholipase A2 receptor (PLA2R) antibody is highly specific and can be detected in more than 70% of active idiopathic MGN, and may predict its recurrence too (19) . PLA2R antibody was negative in our patient and kidney biopsy finding was not compatible, hence we ruled out the recurrence of MGN. For further evaluation second allograft biopsy was conducted. Patients with de novo MCD had a broad variety of primary diseases in native kidneys. Primary disease of our patient was idiopathic MGN. Among previous published papers, 2 of them had MGN as the original disease (9, 10) . In most cases, de novo MCD is identified by symptoms and signs of nephrotic syndrome that has usually occurred suddenly. All of reported cases of de novo MCD had nephrotic range proteinuria and most of their renal allograft function were preserved (6) (7) (8) (9) (10) (11) (12) . Our patient presented with early expulsive onset of nephrotic syndrome. The second biopsy was consistent with MCD. There is no recommendation for standard treatment of de novo MCD. Acceptable response rate to high dose steroid was reported and usually the patient will become free of proteinuria within two to three weeks. Treatment modalities included calcium channel (non-DHP) blockers, renin-angiotensin system inhibitors, lowering the dose of calcineurin inhibitors, continuing of immunosuppressive medication and starting other anti-proteinuric drugs (6-11). Altogether, de novo MCD has been reported as a complication with a propitious prognosis. Except for a few cases, most cases of de novo MCD had responded to different treatments. Zafarmand et al reported 12 out of 14 de novo MCD cases reached complete remission while no impairment of renal allograft function was occurred (8) . According to the course of the disease, we did not expect that our patient shows focal segmental glomerulosclerosis. Finally our patient had less than 100 mg proteinuria per day with a stable kidney function and discharged accordingly.
Conclusion
In conclusion, the prognosis of de novo MCD is favorable. Significant amelioration of proteinuria with a stable renal function is detectable in most of the cases.
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